A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid TumorsPhilippe L. Bédard, Cristiana Sessa, Luis Paz‐Ares et al.|Clinical Cancer Research|2014Cited by 326
First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid TumorsCristiana Sessa, Udai Banerji, Geoffrey I. Shapiro et al.|Clinical Cancer Research|2013Cited by 160